When Cell and Gene Therapies Surge to Market, How Resilient Will Your Cell Sourcing Infrastructure Be?
Nullam velit nulla commodo sem, at egestas nulla metus vel imperdiet aptent taciti ad litora torquent per.
Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All
Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of: Efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes HLA complexity in cell source selection How machine…
The Historical HLA Learning Curve
Human leukocyte antigens (HLAs), which are proteins found on the surface of most human cells, are fundamental to the success of matching potentially life-saving donors with patients in need of a blood stem cell transplant. Immune cells use HLAs to protect one’s own cells from invading microbes and viruses. A properly functioning immune system will…
Strategies to Advance the Donor Selection Process for Cell Therapies to Improve Outcomes
HLA matching in the development of leading-edge allogeneic therapeutics and cellular therapies—and hematopoietic stem cell transplantation (HSCT)—isn’t only about finding the best matches. It’s also about avoiding mismatches that could result in less optimal patient outcomes. During this on-demand webinar you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal and…
Size Matters: Ensuring Donor Pool Sustainability and Cell Therapy Supply Chain Success When Scaling Up and Out
View this on-demand webinar to learn how to increase potential for long-term success in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to large volumes, while also managing…
Scalability Considerations When Using Cord Blood as an Allogeneic Starting Material
Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. During this hour long on-demand webinar, our panelists discuss: Why it’s essential to have a good understanding of critical starting…
Novel Allogeneic Cellular Therapies: Predictions for the Future
The ONE Forum 2021: On-demand session Over the last several years, there has been increasing global investment in the development of novel allogeneic cell and gene therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 allogeneic cellular therapies are under development across the globe, many of which are…
Navigating Scalability and Consistency in the Allogeneic Supply Chain
Watch this on-demand webinar for an in-depth discussion on these questions and more. You’ll walk away with insights on navigating the scalability of donor starting material as the allogeneic cell therapy industry grows. PANELISTS Abby Waters, PhD Senior Manager, Solutions Owner NMDP BioTherapies℠ Dean A. Lee, MD, PhD Physician, Hematology and Oncology Director of the…
Modeling an Allogeneic Cell Bank Size and Use Pattern
An NMDP BioTherapies℠ client was like many allogeneic cell and gene therapy developers. It was developing a therapy for a blood condition and needed to build an off-the-shelf bank of cryopreserved cell sources. The client needed to understand: HLA genotypes to cover most patients in the U.S. How many patients would be covered by cells…